AzTrials
AzTrials

AnemiaNCT02031614

The Immunomodulatory Effects of Phlebotomy

A study testing Phlebotomy in people with Anemia, run by Radboud University Medical Center at 1 site in Netherlands.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Although phlebotomy is routinely performed in blood donors, and seemingly does not have significant health risks, it is highly relevant to know what the effect of phlebotomy is on immunity. Read more about this study

Who is it for?
Ages 18 to 35 years, men onlyHealthy volunteers can take part
Conditions the study is for
Anemia
What is being tested?
Phlebotomy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteNetherlands
Study dates
Jan 2014to May 2014
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 35 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Male
  • Age >18 and <36 years
  • Healthy as concluded from medical history

Who cannot join

  • Having donated blood to the blood bank within one year preceding phlebotomy
  • Significant blood loss from trauma within one year preceding phlebotomy
  • Having lost > 100 ml of blood due to any cause, within 3 months preceding phlebotomy (not counting blood withdrawn during screening visit)
  • Having lost > 50 ml of blood due to any cause, within 1 month preceding phlebotomy (not counting blood withdrawn during screening visit)
  • Having lost >20 ml blood due to any cause, within 1 week preceding phlebotomy (not counting blood withdrawn during screening visit)
  • Family history of thallasemia, sickle cell disease, hereditary hemochromatosis, or iron refractory iron deficiency anemia
  • Signs of history of infection within 2 weeks preceding phlebotomy
  • History of frequent vasovagal response

Trial locations and contacts

1 site in 1 country.

L T van Eijk, MD, MSc contact

+31 24 3653879

L.vanEijk@Radboudumc.nl

Netherlands1 site
  • Radboudumc

    Nijmegen, Gelderland, 6500 HB

    L T van Eijk, MD, MSc, +31 24 3617273

    P Pickkers, MD, PhD

Other trials in Netherlands

About this study

Although phlebotomy is routinely performed in blood donors, and seemingly does not have significant health risks, it is highly relevant to know what the effect of phlebotomy is on immunity. Alterations in immunity due to phlebotomy could have beneficial effects, like the suppression of the low grade inflammatory process that contributes to atherosclerosis, but in theory could also contribute to a suppressed innate immune response that could increase the risk of infection. This is not only relevant for blood donors, but also for patients suffering from blood loss and for daily clinical practice in which blood is routinely drawn of patients for laboratory determinations.

Read the detailed description

The loss of blood by haemorrhage or routine phlebotomy as performed during blood donation by healthy volunteers, has large effects on systemic iron homeostasis. The relative shortage of erythrocytes after blood loss is compensated for by increasing the production of new red cells by the bone marrow. As iron is needed for effective haemoglobin synthesis, the transport of iron to the bone marrow needs to be increased. This is accomplished by the suppression of hepcidin production in the liver. Hepcidin is the central regulator of iron homeostasis. It can regulate serum iron levels effectively by downregulating iron channel ferroportin on iron exporting cells. Hepcidin production is increased in response to inflammation en high systemic iron content, and is suppressed by increased erythrocyte production, hypoxia, anemia, and low systemic iron content. Therefore, blood loss leads to hepcidin suppression, increased release of iron into the circulation and decrease of iron stores.

Alterations in iron metabolism can have immunomodulatory effects. The intra cellular iron content in macropahges and monocytes, has shown pro-inflammatory effects in several investigations. Hepcidin is reported to have pro-inflammatory effects in some reports, and anti-inflammatory effects in others.

Although phlebotomy is routinely performed in blood donors, and seemingly does not have significant health risks, it is highly relevant to know what the effect of phlebotomy is on immunity. Alterations in immunity due to phlebotomy could have beneficial effects, like the suppression of the low grade inflammatory process that contributes to atherosclerosis, but in theory could also contribute to a suppressed innate immune response that could increase the risk of infection. This is not only relevant for blood donors, but also for patients suffering from blood loss and for daily clinical practice in which blood is routinely drawn of patients for laboratory determinations.

Objective: To assess the ex vivo cytokine production of whole blood during 28 days after phlebotomy (routine withdrawal of 500 ml of blood).

Study design: Intervention study in 10 healthy male volunteers.

Study population: 10 healthy male volunteers in the age of 18-35 years.

Intervention (if applicable): Withdrawal of 500 mL of blood at the blood bank (Sanquin, Nijmegen, The Netherlands).

Main study parameters/endpoints:

  • Ex vivo cytokine production of whole blood, drawn on day -1, 0, 1, 3, 5, 7, 14, 21, 28.
  • Hemoglobin, hematocrit, white blood cell count and differential
  • Hepcidin
  • Iron parameters (serum iron, transferrin saturation, ferritin)

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

10 healthy young male volunteers will be included in this study. The study consists of 10 visits: 1 screening visit and 9 follow-up visits. The screening visit consists of a medical history questionnaire. On day 0, Phlebotomy of 500 ml of blood will be performed at the Sanquin blood bank, Nijmegen according to normal procedures. Risks associated with phlebotomy are, discomfort during puncture, light-headedness, orthostatic hypotension, vasovagale response, and hematoma at the puncture site.

On day -1, 0, 1, 3, 5, 7, 14, 21 and 28, a volume of 7 mL of blood will be drawn by venapuncture. Associated risks are discomfort during puncture , vasovagale response, and hematoma at the puncture site.

Conditions
Anemia
Being tested
Phlebotomy
Keywords
anemia, blood withdrawal, phlebotomy, innate immunity, Immune reponse
Medical subject headings
Anemia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PhlebotomyProcedure or surgery

    Withdrawal of 500 mL of whole blood.

Study groups in NCT02031614
Study groupRoleWhat they receive
PhlebotomyExperimentalSubjects in this arm will undergo phlebotomy of 500 mL of blood.
Receives: Procedure: Phlebotomy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. ex vivo TNF-afpha production of whole blood in reponse to incubation with E. Coli LPS

    Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.

    Measured: 1 day before till 28 days after phlebotomy

Secondary outcomes (6)
  1. ex vivo IL6 and IL-10 production of whole blood in response to incubation with E.Coli LPS

    Blood will be drawn on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 after phlebotomy, to assess ex vivo cytokine production.

    Measured: 1 day before till 28 days after phlebotomy

  2. Changes in hemoglobin, hematocrit, white blood cell count and differential

    Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following the withdrawal of 500 ml of blood at the blood bank

    Measured: 1 day before till 28 after phlebotomy

  3. Changes in hemoglobin, hematocrit, white blood cell count and differential

    Hemoglobin, hematocrit, white blood cell count and differential will be determined on day -1, 0, 1, 3, 5, 7, 14, 21 and 28 following phlebotomy

    Measured: 1 day before till 28 after phlebotomy

  4. Changes in plasma hepcidin

    Plasma hepcidin concentration will be determined at various time points during the 28 days of follow-up, following phlebotomy

    Measured: 1 day before till 28 after phlebotomy

  5. Changes in other markers of iron homeostasis (serum iron, transferrin saturation, ferritin)

    Changes in parameters of iron homeostasis will be determined at various time points during the 28 days of follow-up, following phlebotomy

    Measured: 1 day before till 28 after phlebotomy

  6. Adverse Events

    Adverse Events will be assessed with every visit

    Measured: 1 day before till 28 after phlebotomy

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted9 Jan 2014 (estimated)
  2. Study startJan 2014
  3. Primary completionMay 2014 (estimated)
  4. Study completionMay 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02031614
Sponsor's protocol ID
Phlebotomy-2014
Status last verified
Jan 2014
First submitted
8 Jan 2014
Last updated
9 Jan 2014
Results posted
No
Data monitoring committee
Yes

Questions about this trial

What is this clinical trial studying?

A study testing Phlebotomy in people with Anemia, run by Radboud University Medical Center at 1 site in Netherlands.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 9 Jan 2014. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact L T van Eijk, MD, MSc (+31 24 3653879, L.vanEijk@Radboudumc.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

ex vivo TNF-afpha production of whole blood in reponse to incubation with E. Coli LPS (time frame: 1 day before till 28 days after phlebotomy). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Jan 2014.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in